Could a common antibiotic boost Chemo's power against breast cancer?

NCT ID NCT06452394

Recruiting now Disease control Sponsor: Swiss Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with early-stage ER+/HER2- breast cancer. It tests whether adding doxycycline, a safe and inexpensive antibiotic, to standard chemotherapy can better target cancer stem cells—cells that may cause the cancer to come back. About 50 participants will receive doxycycline alongside their usual chemo before surgery. The goal is to see if this combination improves the chance of eliminating all cancer cells.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Centre Hospitalier Universitaire Vaudois (CHUV)
RECRUITING

Lausanne, CH-1011, Switzerland
Clinique de Genolier
RECRUITING

Genolier, Canton of Vaud, 1272, Switzerland
Kantonsspital Graubünden
RECRUITING

Chur, Kanton Graubünden, 7000, Switzerland
Kantonsspital St.Gallen
RECRUITING

Sankt Gallen, Canton of St. Gallen, 9007, Switzerland
Kantonsspital Winterthur
RECRUITING

Winterthur, Canton of Zurich, 8401, Switzerland
Réseau du sein Lausanne
RECRUITING

Lausanne, 1004, Switzerland
Tumor Zentrum Aarau
RECRUITING

Aarau, 5000, Switzerland
Tumor- und Brustzentrum Ostschweiz
RECRUITING

Sankt Gallen, 9016, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.